Skip to main content
SpringerLink
Log in

Consolidative Radiation in DLBCL: Evidence-Based Recommendations

  • Lymphomas (PA Hamlin, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Radiation therapy (RT) has been described as the most effective single agent in the treatment of lymphoma; however, contemporary lymphoma treatment rarely relies on single agents. In the modern era, the selection of appropriate patients for combined modality therapy has become increasingly complex over the last decade with the transition to immunochemotherapy, the emergence of functional imaging for response evaluation, and the improvement in conformal avoidance of normal tissues when delivering RT. Recent evidence demonstrates that selected patients with DLBCL have significantly better outcomes when RT is added to immunochemotherapy; however, there are important knowledge gaps regarding the use of functional imaging to facilitate treatment selection. This article will review the current evidence regarding the optimal use of combined modality therapy for DLBCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(22):5027–33.

    Article  CAS  Google Scholar 

  2. Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, et al. Long-term solid cancer risk among five-year survivors of Hodgkin’s lymphoma. J Clin Oncol. 2007;25(12):1489–97.

    Article  PubMed  Google Scholar 

  3. Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW, et al. Risk of second malignancy after non-Hodgkin’s lymphoma: a British cohort study. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(10):1568–74.

    Article  Google Scholar 

  4. Moser EC, Noordijk EM, van Leeuwen FE, Baars JW, Thomas J, Carde P, et al. Risk of second cancer after treatment of aggressive non-Hodgkin’s lymphoma; an EORTC cohort study. Haematologica. 2006;91(11):1481–8.

    PubMed  Google Scholar 

  5. Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Gobbi PG, et al. Second malignancies after treatment of diffuse large B-cell non-Hodgkin’s lymphoma: a GISL cohort study. Haematologica. 2008;93(9):1335–42.

    Article  PubMed  Google Scholar 

  6. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339(1):21–6.

    Article  CAS  PubMed  Google Scholar 

  7. Miller T, Leblanc M, Spier C, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin’s lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial. Blood 2001;98(724a).

  8. Horning SJ, Weller E, Kim K, Earle JD, O’Connell MJ, Habermann TM, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern cooperative oncology group study 1484. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(15):3032–8.

    Article  CAS  Google Scholar 

  9. Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352(12):1197–205.

    Article  CAS  PubMed  Google Scholar 

  10. Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thieblemont C, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(7):787–92.

    Article  CAS  Google Scholar 

  11. Moser EC, Noordijk EM, van Leeuwen FE, le Cessie S, Baars JW, Thomas J, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2006;107(7):2912–9.

    Article  CAS  PubMed  Google Scholar 

  12. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–16. A randomized trial of 1222 elderly patients comparing 6–8 cycles of CHOP with or without rituximab. The addition of rituximab to 6 cycles of CHOP improved 3-year EFS by 19.3 % and 3-year OS by 10.4 %. Patients with bulk (≥7.5 cm) or extranodal disease received RT.

    Article  CAS  PubMed  Google Scholar 

  13. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–22. Randomized trial including 813 patients aged 18–60 assigned CHOP with or without rituximab. 6-year event-free survival was 55 · 8 % for patients treated with CHOP alone and 74 · 3 % for those recieiving R-CHOP; p < 0 · 0001).

    Article  CAS  PubMed  Google Scholar 

  14. Held G, Murawski N, Ziepert M, Fleckenstein J, Poschel V, Zwick C, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(11):1112–8. A prospective trial of 166 patients evaluating the effect of omitting RT among patients achieving Cr/CRu with R-CHOP chemotherapy. Compared to patients on the RICOVER trial (who received RT), the omission of RT among patients with bulk was associated with significantly worse 3-year EFS (54 % vs. 80 %; P = .001), PFS (62 % vs. 88 %; P < .001) and OS (65 % vs. 90 %; P = .001).

    Article  Google Scholar 

  15. Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008;9(5):435–44.

    Article  PubMed  Google Scholar 

  16. Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(14):2258–63.

    Article  CAS  Google Scholar 

  17. Tondini C, Zanini M, Lombardi F, Bengala C, Rocca A, Giardini R, et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin’s lymphomas. J Clin Oncol Off J Am Soc Clin Oncol. 1993;11(4):720–5.

    CAS  Google Scholar 

  18. Shenkier TN, Voss N, Fairey R, Gascoyne RD, Hoskins P, Klasa R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(1):197–204.

    Article  CAS  Google Scholar 

  19. Tomita N, Takasaki H, Miyashita K, Fujisawa S, Ogusa E, Matsuura S, et al. R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma. Br J Haematol. 2013;161(3):383–8.

    Article  CAS  PubMed  Google Scholar 

  20. Lamy T, Damaj G, Gyan E, Soubeyran P, Bouabdallah K, Cartron G, et al. R-CHOP with or without radiotherapy in non-bulky limited-stage Diffuse Large B Cell Lymphoma (DLBCL): preliminary results of the prospective randomized phase III 02–03 Trial from the Lysa/Goelams Group. https://ash.confex.com/ash/2014/webprogram/Paper69734.html Accessed Jun3 6, 2015. 2014; American Society of Hematology, abstract 393.

  21. Marcheselli L, Marcheselli R, Bari A, Liardo EV, Morabito F, Baldini L, et al. Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2011;52(10):1867–72.

    Article  CAS  PubMed  Google Scholar 

  22. Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, et al. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86(3):569–77.

    Article  PubMed  Google Scholar 

  23. Phan J, Mazloom A, Abboud M, Salehpour M, Reed V, Zreik T, et al. Consolidative radiation therapy for stage III Hodgkin lymphoma in patients who achieve complete response after ABVD chemotherapy. Am J Clin Oncol. 2011;34(5):499–505.

    PubMed  Google Scholar 

  24. Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, et al. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the national comprehensive cancer network lymphoma outcomes project. Cancer. 2015;121(7):1032–9.

    Article  CAS  PubMed  Google Scholar 

  25. Held G, Zeynalova S, Murawski N, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(32):4115–22. Analysis of 292 patients with skeletal involvement treated on German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) trials (total sample size 3,840). Among 161 patients who achieved a CR, CR unconfirmed, or PR to immunochemotherapy, patients who received RT to sites of skeletal involvement had a better 3-year EFS (75 % v 36 %; P < 0.001), and OS (86 % v 71 %; P = 0.064) than those treated with systemic therapy alone.

    Article  CAS  Google Scholar 

  26. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(5):571–8.

    Article  Google Scholar 

  27. Barrington SF, Mikhaeel NG. When should FDG-PET be used in the modern management of lymphoma? Br J Haematol. 2014;164(3):315–28.

    Article  PubMed  Google Scholar 

  28. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(27):3059–68.

    Article  Google Scholar 

  29. Dorth JA, Prosnitz LR, Broadwater G, Diehl LF, Beaven AW, Coleman RE, et al. Impact of consolidation radiation therapy in stage III–IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. Int J Radiat Oncol Biol Phys. 2012;84(3):762–7.

    Article  PubMed  Google Scholar 

  30. Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(27):4170–6. Analysis of 469 patients with DLBCL treated with or without RT. Matched-pair analyses of patients who received six to eight cycles of R-CHOP with stage I or II disease (44 pairs) and all stages (74 pairs) indicated that RT improved OS (hazard ratio [HR], 0.52 and 0.29, respectively) and PFS (HR, 0.45 and 0.24, respectively) compared with no RT.

    Article  Google Scholar 

  31. Dorth JA, Chino JP, Prosnitz LR, Diehl LF, Beaven AW, Coleman RE, et al. The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans. Ann Oncol. 2011;22(2):405–10.

    Article  CAS  PubMed  Google Scholar 

  32. Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, et al. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys. 2012;83(5):e647–54.

    Article  PubMed  Google Scholar 

  33. Sehn L, Klasa R, Shenkier T, et al. Long-term experience with pet-guided consolidative radiation therapy (XRT) in patients with advancedstage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. Hematol Oncol. 2013;31(Supp1):137. abstract 123.

  34. Laurie H Sehn, Edward L G Hardy, Karamjit K Gill, Abdulwahab J Al-Tourah, Jesse Shustik, Nicol A Macpherson, et al. Phase 2 trial of interim PET scan-tailored therapy in patients with advanced stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). https://ash.confex.com/ash/2014/webprogram/Paper76195.html; Accessed June 8, 2015. 2014.

  35. Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92.

    Article  PubMed  Google Scholar 

  36. Dorth JA, Prosnitz LR, Broadwater G, Beaven AW, Kelsey CR. Radiotherapy dose–response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy. Radiat Oncol. 2012;7:100.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Lao L, Tsang R, Pintilie M, et al. Combined modality therapy for stage I–II diffuse large B-cell lymphoma provides excellent local control and clinical outcome in the rituximab era. Eur J Cancer. 2011;37(Supp 1):S644. abstract 2919.

  38. Krol AD, Berenschot HW, Doekharan D, Henzen-Logmans S, van der Holt B, van’t Veer MB. Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin’s lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy. Radiother Oncol. 2001;58(3):251–5.

    Article  CAS  PubMed  Google Scholar 

  39. Wilder RB, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas F, et al. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer. 2001;91(12):2440–6.

    Article  CAS  PubMed  Google Scholar 

  40. Kamath SS, Marcus Jr RB, Lynch JW, Mendenhall NP. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 1999;44(3):563–8.

    Article  CAS  PubMed  Google Scholar 

  41. Tseng YD, Chen Y, Catalno PJ, et al. Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015;91(1):223–31.

    Article  PubMed  Google Scholar 

  42. Martens C, Hodgson DC, Wells WA, Sun A, Bezjak A, Pintilie M, et al. Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2006;64(4):1183–7.

    Article  PubMed  Google Scholar 

  43. Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2014;89(1):49–58.

    Article  PubMed  Google Scholar 

  44. Alcorn S, Agbahiwe H, Terezakis S. Non-Hodgkin lymphoma. In: Lee NY, Riaz N, Lu J, editors. Target volume delineation for conformal and intensity modulated radiation therapy. Switzerland: Springer International; 2014.

    Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

David C. Hodgson and N. George Mikhaeel declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada

    David C. Hodgson

  2. Radiation Medicine Program, Princess Margaret Cancer Centre, 610 University Ave, Toronto, ON, M5G 2M9, Canada

    David C. Hodgson

  3. Lymphoma Unit, Guy’s & St Thomas’ NHS Foundation Trust, London, UK

    N. George Mikhaeel

Authors
  1. David C. Hodgson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. George Mikhaeel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David C. Hodgson.

Additional information

This article is part of the Topical Collection on Lymphomas

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hodgson, D.C., Mikhaeel, N.G. Consolidative Radiation in DLBCL: Evidence-Based Recommendations. Curr Oncol Rep 17, 49 (2015). https://doi.org/10.1007/s11912-015-0472-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-015-0472-y

Keywords

Search

Navigation